Iqvia Holdings Inc (IQV) Holdings Trimmed by Corsair Capital Management L.P.

Corsair Capital Management L.P. trimmed its position in shares of Iqvia Holdings Inc (NYSE:IQV) by 6.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 197,046 shares of the medical research company’s stock after selling 13,286 shares during the quarter. Iqvia makes up about 5.9% of Corsair Capital Management L.P.’s investment portfolio, making the stock its 3rd biggest position. Corsair Capital Management L.P. owned 0.10% of Iqvia worth $25,565,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Cutler Group LP lifted its position in shares of Iqvia by 173.3% during the second quarter. Cutler Group LP now owns 1,100 shares of the medical research company’s stock worth $109,000 after purchasing an additional 2,600 shares in the last quarter. Fort L.P. acquired a new position in shares of Iqvia during the second quarter worth approximately $118,000. Hamilton Lane Advisors LLC acquired a new position in shares of Iqvia during the third quarter worth approximately $121,000. Quad Cities Investment Group LLC acquired a new position in shares of Iqvia during the second quarter worth approximately $140,000. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Iqvia by 177.2% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,156 shares of the medical research company’s stock worth $150,000 after purchasing an additional 739 shares in the last quarter. 89.33% of the stock is currently owned by hedge funds and other institutional investors.

IQV opened at $121.85 on Friday. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $24.64 billion, a price-to-earnings ratio of 27.95, a PEG ratio of 1.77 and a beta of 0.81. Iqvia Holdings Inc has a twelve month low of $91.57 and a twelve month high of $135.48.



Iqvia (NYSE:IQV) last posted its earnings results on Monday, October 22nd. The medical research company reported $1.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.03. The company had revenue of $2.59 billion for the quarter, compared to analyst estimates of $2.58 billion. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. Iqvia’s revenue for the quarter was up 5.2% on a year-over-year basis. Research analysts predict that Iqvia Holdings Inc will post 5.13 earnings per share for the current year.

Several brokerages recently weighed in on IQV. Zacks Investment Research upgraded shares of Iqvia from a “hold” rating to a “buy” rating and set a $142.00 price objective on the stock in a report on Tuesday, October 23rd. Morgan Stanley increased their price objective on shares of Iqvia from $130.00 to $145.00 and gave the company an “overweight” rating in a report on Monday. Piper Jaffray Companies increased their price objective on shares of Iqvia to $131.00 and gave the company a “neutral” rating in a report on Tuesday, October 23rd. Wells Fargo & Co increased their price objective on shares of Iqvia from $120.00 to $140.00 and gave the company an “outperform” rating in a report on Monday, August 13th. Finally, Barclays increased their price objective on shares of Iqvia from $130.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, October 23rd. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Iqvia currently has an average rating of “Buy” and an average target price of $134.41.

In other Iqvia news, Director John G. Danhakl sold 370,470 shares of the stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $124.83, for a total value of $46,245,770.10. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Michael R. Mcdonnell sold 9,500 shares of the stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $128.35, for a total transaction of $1,219,325.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 7,117,903 shares of company stock worth $881,082,166. Company insiders own 6.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Iqvia Holdings Inc (IQV) Holdings Trimmed by Corsair Capital Management L.P.” was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://dakotafinancialnews.com/2018/12/07/iqvia-holdings-inc-iqv-holdings-trimmed-by-corsair-capital-management-l-p.html.

Iqvia Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Recommended Story: Earnings Reports

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply